Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
17 angezeigte Treffer · Seite 7, keine Gesamtzahl für „Lenvima“
Suchtreffer
Begriffe & Kennungen
Lenvima · 4.8 · Summary of the safety profile
Eintrag öffnenLenvima · 4.8 · System Organ Class Lenvatinib monotherapy Combination with pembrolizumab (MedDRA terminology) Cardiac disorder
Eintrag öffnenLenvima · 4.8 · System Organ Class Lenvatinib monotherapy Combination with pembrolizumab (MedDRA terminology) General disorder
Eintrag öffnenLenvima · 4.8 · System Organ Class Lenvatinib monotherapy Combination with pembrolizumab (MedDRA terminology) Hepatobiliary di
Eintrag öffnenLenvima · 4.8 · System Organ Class Lenvatinib monotherapy Combination with pembrolizumab (MedDRA terminology) Infections and i
Eintrag öffnenLenvima · 4.8 · Table 6 Adverse reactions reported in patients treated with lenvatinib§
Eintrag öffnenLenvima · 4.8 · Tabulated list of adverse reactions
Eintrag öffnenLenvima · 4.8 · The following terms have been combined: a: Thrombocytopenia includes thrombocytopenia and decreased platelet c
Eintrag öffnenLenvima · 4.8 · The median time to first onset in lenvatinib-treated patients was 10.1 weeks. No differences between lenvatini
Eintrag öffnenLenvima · 4.8 · The most common (occurring in ≥5% of patients) severe (Grade ≥3) adverse reactions were hypertension (37.2%),
Eintrag öffnenLenvima · 4.8 · The most frequently reported adverse reactions (occurring in ≥30% of patients) are hypertension (44.0%), diarr
Eintrag öffnenLenvima · 4.8 · The most frequently reported adverse reactions (occurring in ≥30% of patients) are hypertension (68.6%), diarr
Eintrag öffnenLenvima · 4.8 · The most important serious adverse reactions were hepatic failure (2.8%), hepatic encephalopathy (4.6%), oesop
Eintrag öffnenLenvima · 4.8 · The most important serious adverse reactions were renal failure and impairment (2.4%), arterial thromboembolis
Eintrag öffnenLenvima · 4.8 · The safety of lenvatinib in combination with pembrolizumab has been evaluated in 530 patients with advanced EC
Eintrag öffnenLenvima · 4.8 · The safety profile of lenvatinib as combination therapy is based on data from 530 EC patients treated with len
Eintrag öffnenLenvima · 4.8 · The safety profile of lenvatinib as monotherapy is based on data from 452 DTC patients and 496 HCC patients; a
Eintrag öffnen